Notable UK Pharmaceutical Companies (and what manufacturing insurance typically needs to cover)

  • Home
  • Blog
  • Notable UK Pharmaceutical Companies (and what manufacturing insurance typically needs to cover)

Notable UK Pharmaceutical Companies (and what manufacturing insurance typically needs to cover)

CALL FOR EXPERT ADVICE
GET A QUOTE NOW
CALL FOR EXPERT ADVICE
GET A QUOTE NOW
The UK pharmaceutical sector is one of the country’s most important advanced manufacturing industries. It spans global “big pharma” operations, high-growth biotech, contract development and manufacturing organisations (CDMOs), specialist sterile manufacturers, and companies producing everything from small-molecule medicines to complex biologics.
If you’re involved in pharmaceutical manufacturing—whether you’re producing active pharmaceutical ingredients (APIs), finished dose forms, clinical trial materials, or packaging and labelling—your insurance needs are rarely “off-the-shelf”. The risk profile is shaped by strict regulation, high-value stock, temperature-controlled storage, complex supply chains, and the potential for product-related claims.
In this blog, we’ll look at a selection of notable UK pharmaceutical companies (and UK-based operations), then break down the types of manufacturing insurance that typically matter most in the pharma world. This is written as general guidance, not a statement of any company’s insurance arrangements.
  1. Notable UK pharmaceutical companies and UK-based pharma manufacturers
AstraZeneca (UK headquarters: Cambridge) AstraZeneca is one of the UK’s best-known global pharmaceutical companies, with major UK operations and a significant presence in R&D and manufacturing. Large pharma groups like AstraZeneca typically manage complex global supply chains, multiple manufacturing sites, and high regulatory scrutiny. From an insurance standpoint, the scale of operations often means layered programmes, global product liability considerations, and robust business interruption planning.
GSK (GlaxoSmithKline) (UK headquarters: London; major UK sites historically across England) GSK is another flagship UK pharma company with a long history in medicines and vaccines. Vaccine and biologics-related operations can bring additional considerations such as cold chain exposures, contamination risks, and specialist equipment breakdown. Even where manufacturing is partly outsourced, the brand owner can still face product liability and recall exposures.
Hikma Pharmaceuticals (UK operations; global group with a strong UK footprint) Hikma is known for generics and injectable medicines, among other areas. Sterile injectables and complex formulations can raise the stakes for quality control, contamination prevention, and batch integrity. Insurance programmes in this space often focus heavily on product liability, product recall, and business interruption tied to specialist plant.
Indivior (UK-based specialty pharma) Indivior is a UK-based specialty pharmaceutical company. Specialty pharma can involve narrower product portfolios, which can concentrate risk: if one product line is disrupted, revenue impact can be immediate. That makes business interruption, supply chain resilience, and contingent business interruption (cover for supplier/customer disruption) particularly relevant.
Dechra Pharmaceuticals (UK-based; veterinary pharmaceuticals) While veterinary pharma differs from human medicines, it still involves regulated manufacturing, product safety, and supply chain risk. Depending on product types, there may be heightened attention on product liability, product recall, and regulatory compliance costs.
Recipharm (UK sites; CDMO) CDMOs manufacture for other companies, often under contract, and may handle clinical trial materials, sterile products, or specialist dose forms. Contractual liability, professional indemnity (where services include development/technical advice), and careful alignment of liability between brand owner and manufacturer become key. A CDMO’s insurance needs to match the contracts they sign, including indemnities, limits, and jurisdiction requirements.
Thermo Fisher Scientific (UK manufacturing and life sciences operations) Thermo Fisher is a major life sciences player with UK presence across manufacturing, services, and supply. The risk mix can include manufacturing, distribution, and service components. Insurance often needs to address property damage and business interruption, product liability, and potentially errors and omissions exposures depending on the services provided.
Piramal Pharma Solutions (UK presence; CDMO) Piramal has a UK footprint in pharma services and manufacturing. As with other CDMOs, the key is mapping responsibilities: who owns the specification, who releases the batch, who controls labelling, and who holds the marketing authorisation. Those details drive where liability can land.
Quotient Sciences (UK-based; drug development and manufacturing services) Companies that combine development services with manufacturing can face a blend of exposures: lab and clinical-related risks, manufacturing risks, and professional services risks. Insurance may need to combine product liability with professional indemnity and clinical trial-related covers (where relevant).
Catalent (UK sites; CDMO) Catalent has had UK operations providing manufacturing and development services. The more complex the formulation and delivery system, the more important it is to consider specialist equipment, contamination controls, and the knock-on business interruption impact if a line is down.
Boehringer Ingelheim (UK operations; global pharma with UK footprint) Many global pharma groups have UK manufacturing, packaging, or distribution operations. For UK-based sites, the insurance focus often includes property and business interruption, employer’s liability, and UK-specific regulatory and contractual requirements—even if the parent group runs a global programme.
Pfizer (UK operations; global pharma with UK footprint) Similarly, global groups with UK sites may have local operational risks that need to be correctly declared and covered. It’s common for UK sites to have high-value stock, specialist plant, and strict quality environments, which can drive property and BI values.
Roche (UK operations; global pharma with UK footprint) Roche’s UK presence is often associated with diagnostics and pharma. Where manufacturing or specialist handling is involved, the risk profile can include temperature control, high-value components, and supply chain dependencies.
Sanofi (UK operations; global pharma with UK footprint) UK operations for global manufacturers can include packaging, distribution, or manufacturing. Even if a UK site is “only” packaging or secondary manufacturing, mislabelling and packaging errors can still trigger costly recall events.
Note: The UK also has a large ecosystem of smaller manufacturers, specialist sterile facilities, API producers, and biotech scale-ups. These businesses can be just as exposed—sometimes more so—because a single incident can have a disproportionate financial impact.
  1. What “manufacturing insurance” usually means for pharma
When people say “manufacturing insurance”, they often mean a bundle of covers that protect the business if something goes wrong at the site, in the supply chain, or with the product itself. In pharmaceutical manufacturing, the consequences of disruption can be severe because:
  • Stock is high value and may be time/temperature sensitive
  • Production environments are specialised and expensive to repair
  • Quality systems are tightly regulated (GMP expectations)
  • A single batch issue can affect multiple customers or markets
  • Contractual penalties and reputational damage can be significant
The right solution depends on what you manufacture (API vs finished dose), how you manufacture it (sterile vs non-sterile), and your role in the chain (brand owner vs CDMO vs packager).
  1. Core covers pharma manufacturers commonly consider
A) Property damage (buildings, plant, equipment, stock) Property insurance is the base layer: it covers physical loss or damage to insured property caused by insured perils (for example, fire, flood, escape of water, storm, theft—depending on the policy).
Pharma-specific points to watch:
  • High-value specialist machinery (granulators, tablet presses, filling lines, isolators)
  • Cleanrooms and controlled environments (HVAC, filtration, validation)
  • Stock values, including work-in-progress and finished goods
  • Temperature-controlled storage and cold rooms
  • Utilities and services (compressed air, purified water systems, steam)
B) Business interruption (BI) BI covers loss of gross profit (or revenue, depending on the basis) following insured property damage. For pharma, BI is often where the biggest financial impact sits because downtime can be long—especially if revalidation is required after repairs.
Pharma-specific points to watch:
  • Indemnity period: 12 months can be too short; 18–24 months may be more realistic for complex lines
  • Increased cost of working: costs to keep trading (outsourcing, overtime, expedited shipping)
  • Claims preparation costs
  • Dependencies on single lines or single sites
C) Equipment breakdown (engineering) Equipment breakdown (sometimes called machinery breakdown) covers sudden and accidental breakdown of plant and machinery, which may not be covered under standard property wording.
Pharma-specific points to watch:
  • Critical utilities (chillers, boilers, compressors)
  • Sterile filling lines and isolators
  • Control systems and automation
  • Resulting BI (often added as “machinery breakdown BI”)
D) Product liability Product liability covers legal liability for injury or property damage caused by your products. In pharma, product liability is a cornerstone cover. Even where a manufacturer is not the brand owner, they can still face claims—especially in a contractual dispute or where negligence is alleged.
Pharma-specific points to watch:
  • Jurisdiction and territory (UK-only vs worldwide, US/Canada considerations)
  • Contractual liabilities and indemnities
  • Clinical trial exposures (if applicable)
  • Aggregation: how multiple claims from one batch are treated
E) Product recall / product withdrawal Recall cover can help with the costs of recalling products from the market (or withdrawing them) following an insured trigger. In pharma, recall events can be driven by contamination concerns, stability issues, packaging errors, or labelling mistakes.
Pharma-specific points to watch:
  • Trigger wording: “accidental contamination” vs broader quality defects
  • First-party costs (your recall costs) vs third-party liability
  • Consultant and crisis management costs
  • Disposal and replacement costs (where covered)
F) Employers’ liability (EL) and public liability (PL) In the UK, employers’ liability is compulsory for most businesses with employees. Pharma sites can have exposures related to chemicals, solvents, powders, manual handling, and shift work. Public liability covers injury or property damage to third parties arising from your premises or operations.
Pharma-specific points to watch:
  • COSHH-related exposures and documentation
  • Contractor management (maintenance, validation contractors)
  • Visitor safety in controlled environments
G) Professional indemnity (PI) / errors and omissions (E&O) If you provide services—such as formulation advice, development work, analytical services, or quality consultancy—PI can be relevant. This is especially common for CDMOs and development-focused businesses.
Pharma-specific points to watch:
  • Contractual scope: what you’re warranting in MSAs and quality agreements
  • Fitness for purpose vs reasonable skill and care
  • Worldwide jurisdiction if you serve overseas clients
H) Cyber insurance Pharma manufacturing is increasingly digital: ERP systems, manufacturing execution systems (MES), lab information management systems (LIMS), and connected equipment. Cyber incidents can cause downtime, data loss, and regulatory issues.
Pharma-specific points to watch:
  • Business interruption from cyber events (system outage)
  • Incident response and forensics
  • Data protection exposures (UK GDPR)
  • Supplier-related cyber disruption
I) Directors’ and officers’ (D&O) D&O can be relevant for management liability, particularly for growing companies, companies with investors, or businesses operating in regulated environments.
J) Marine cargo / stock in transit If you ship high-value products, temperature-controlled items, or sensitive materials, cargo cover and transit conditions matter. A small temperature excursion can render stock unusable.
Pharma-specific points to watch:
  • Temperature deviation cover (where available)
  • Packaging standards and data logger requirements
  • Incoterms and who bears the risk in transit
  1. Key underwriting questions insurers often ask pharma manufacturers
If you’re arranging manufacturing insurance for a pharmaceutical business, expect detailed questions. Common areas include:
  • What exactly do you manufacture (API, excipients, finished dose, sterile, non-sterile)?
  • Do you manufacture under GMP, and what certifications/audits do you hold?
  • Are you a brand owner, a contract manufacturer, or both?
  • What are your top products by revenue, and how concentrated is your portfolio?
  • What are your quality systems (batch release, deviation management, CAPA)?
  • What is your contamination control strategy (especially for sterile operations)?
  • What are your fire protections and risk controls (sprinklers, compartmentation)?
  • What are your critical utilities and single points of failure?
  • What is your disaster recovery plan and ability to outsource production?
  • What are your largest customers and key suppliers (and are there alternatives)?
  • What territories do your products go to (UK/EU/US/rest of world)?
The more clearly you can answer these, the easier it is to build a policy that actually responds when it matters.
  1. Common gaps and pitfalls to avoid
Pharma claims can be complex, and gaps often appear in the “grey areas” between covers. A few to watch:
  • BI indemnity period too short: Repairs may be quick, but revalidation and regulatory steps can extend downtime.
  • Understated stock values: Especially where work-in-progress and high-value ingredients are involved.
  • Recall cover not aligned to your real risk: Some policies only respond to narrow triggers.
  • Contractual liabilities not reviewed: CDMOs can sign terms that create exposures beyond standard cover.
  • Territorial limits not matching exports: If products go outside the UK, the liability territory needs to match.
  • Temperature control exposures not properly insured: Cold chain failures can be financially devastating.
  • Supplier dependency not addressed: Contingent BI can be crucial if a single supplier is critical.
  1. Why pharma manufacturing insurance is different from “standard” manufacturing
A general manufacturer might worry most about fire, theft, and public liability. Pharma manufacturers worry about those too—but also about:
  • Batch integrity and traceability
  • Contamination and cross-contamination
  • Regulatory scrutiny and documentation
  • High-value, time-sensitive stock
  • Product recall costs and reputational impacts
  • Complex contractual frameworks between brand owners, CDMOs, and distributors
That’s why it’s important to work with a broker who understands the sector and can translate your operations into an insurance programme that fits.
  1. Practical next steps if you’re a UK pharma manufacturer
If you’re reviewing your insurance, here’s a sensible checklist:
  • Map your process: raw materials → production → QC → release → storage → distribution.
  • Identify single points of failure: one line, one cleanroom, one chiller, one supplier.
  • Confirm stock valuations and BI figures: update them at least annually.
  • Review contracts: especially liability caps, indemnities, and jurisdiction clauses.
  • Stress-test your recall plan: who does what, how quickly, and what it costs.
  • Check cyber resilience: backups, segmentation, incident response plan.
  • Make sure your policy schedule matches reality: sites, activities, turnover, exports.
Conclusion
The UK is home to globally recognised pharmaceutical companies and a deep ecosystem of manufacturers and service providers. Whether you’re a household name or a specialist CDMO, the fundamentals are the same: protect the site, protect cashflow, and protect against product and quality-related liabilities.

Related Blogs

Types of Aerospace Components Factories in the UK

Types of Aerospace Components Factories in the UK

By Insure 24

Types of Aerospace Components Factories in the UK

The UK aerospace supply chain is a web of highly specialised factories—some producing complete structures, others machining tiny safety-critical parts, and many focused on inspection, repair and ce…

Continue Reading
Hospital Bed Manufacturing Insurance: A Complete Guide

Hospital Bed Manufacturing Insurance: A Complete Guide

By Insure 24

Hospital Bed Manufacturing Insurance: A Complete Guide

The hospital bed manufacturing industry plays a critical role in healthcare infrastructure, producing essential equipment that directly impacts patient care and safety. As a manufacturer in this spe…

Continue Reading
Viral Vector Manufacturing Insurance: A Complete Guide

Viral Vector Manufacturing Insurance: A Complete Guide

By Insure 24

Viral Vector Manufacturing Insurance: A Complete Guide

The viral vector manufacturing sector represents one of the most innovative and rapidly expanding areas of biotechnology. As gene therapies, vaccines, and advanced therapeutics continue to revolutio…

Continue Reading